PROTAGONIST THERAPEUTICS INC (PTGX) Fundamental Analysis & Valuation

NASDAQ:PTGX • US74366E1029

Current stock price

104.085 USD
+1.99 (+1.95%)
At close:
104.085 USD
0 (0%)
After Hours:

This PTGX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. PTGX Profitability Analysis

1.1 Basic Checks

  • PTGX had negative earnings in the past year.
  • In the past year PTGX had a positive cash flow from operations.
  • In the past 5 years PTGX reported 4 times negative net income.
  • In multiple years PTGX reported negative operating cash flow during the last 5 years.
PTGX Yearly Net Income VS EBIT VS OCF VS FCFPTGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

1.2 Ratios

  • PTGX has a better Return On Assets (-19.48%) than 76.21% of its industry peers.
  • Looking at the Return On Equity, with a value of -21.17%, PTGX belongs to the top of the industry, outperforming 80.85% of the companies in the same industry.
Industry RankSector Rank
ROA -19.48%
ROE -21.17%
ROIC N/A
ROA(3y)-1.53%
ROA(5y)-18.42%
ROE(3y)-1.29%
ROE(5y)-20.96%
ROIC(3y)N/A
ROIC(5y)N/A
PTGX Yearly ROA, ROE, ROICPTGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60 -80

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PTGX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTGX Yearly Profit, Operating, Gross MarginsPTGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. PTGX Health Analysis

2.1 Basic Checks

  • PTGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, PTGX has more shares outstanding
  • PTGX has more shares outstanding than it did 5 years ago.
  • PTGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PTGX Yearly Shares OutstandingPTGX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
PTGX Yearly Total Debt VS Total AssetsPTGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 72.34 indicates that PTGX is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 72.34, PTGX belongs to the top of the industry, outperforming 97.29% of the companies in the same industry.
  • PTGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 72.34
ROIC/WACCN/A
WACC9.17%
PTGX Yearly LT Debt VS Equity VS FCFPTGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 12.71 indicates that PTGX has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 12.71, PTGX belongs to the best of the industry, outperforming 86.85% of the companies in the same industry.
  • PTGX has a Quick Ratio of 12.71. This indicates that PTGX is financially healthy and has no problem in meeting its short term obligations.
  • PTGX has a better Quick ratio (12.71) than 86.85% of its industry peers.
Industry RankSector Rank
Current Ratio 12.71
Quick Ratio 12.71
PTGX Yearly Current Assets VS Current LiabilitesPTGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. PTGX Growth Analysis

3.1 Past

  • PTGX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -148.81%.
  • Looking at the last year, PTGX shows a very negative growth in Revenue. The Revenue has decreased by -89.41% in the last year.
  • Measured over the past years, PTGX shows a quite strong growth in Revenue. The Revenue has been growing by 9.96% on average per year.
EPS 1Y (TTM)-148.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-134.85%
Revenue 1Y (TTM)-89.41%
Revenue growth 3Y20.07%
Revenue growth 5Y9.96%
Sales Q2Q%-95.64%

3.2 Future

  • The Earnings Per Share is expected to grow by 30.02% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, PTGX will show a very strong growth in Revenue. The Revenue will grow by 63.29% on average per year.
EPS Next Y192.01%
EPS Next 2Y29.39%
EPS Next 3Y34.01%
EPS Next 5Y30.02%
Revenue Next Year764.28%
Revenue Next 2Y74.93%
Revenue Next 3Y74.94%
Revenue Next 5Y63.29%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PTGX Yearly Revenue VS EstimatesPTGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
PTGX Yearly EPS VS EstimatesPTGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

4

4. PTGX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PTGX. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 55.18, the valuation of PTGX can be described as expensive.
  • 89.56% of the companies in the same industry are more expensive than PTGX, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.69, PTGX is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 55.18
PTGX Price Earnings VS Forward Price EarningsPTGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, PTGX is valued cheaper than 89.94% of the companies in the same industry.
Industry RankSector Rank
P/FCF 118.43
EV/EBITDA N/A
PTGX Per share dataPTGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

  • PTGX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as PTGX's earnings are expected to grow with 34.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.39%
EPS Next 3Y34.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PTGX Dividend Analysis

5.1 Amount

  • PTGX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PTGX Fundamentals: All Metrics, Ratios and Statistics

PROTAGONIST THERAPEUTICS INC

NASDAQ:PTGX (4/9/2026, 4:30:01 PM)

After market: 104.085 0 (0%)

104.085

+1.99 (+1.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-04
Inst Owners111.7%
Inst Owner Change0%
Ins Owners1.12%
Ins Owner Change0.91%
Market Cap6.64B
Revenue(TTM)46.02M
Net Income(TTM)-130.15M
Analysts84.21
Price Target114.5 (10.01%)
Short Float %13.09%
Short Ratio10.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.8%
Min EPS beat(2)-38.48%
Max EPS beat(2)4.88%
EPS beat(4)3
Avg EPS beat(4)-1.86%
Min EPS beat(4)-38.48%
Max EPS beat(4)19.4%
EPS beat(8)7
Avg EPS beat(8)87.03%
EPS beat(12)10
Avg EPS beat(12)176.68%
EPS beat(16)13
Avg EPS beat(16)136.62%
Revenue beat(2)1
Avg Revenue beat(2)4.36%
Min Revenue beat(2)-18.32%
Max Revenue beat(2)27.04%
Revenue beat(4)1
Avg Revenue beat(4)-5.05%
Min Revenue beat(4)-20.11%
Max Revenue beat(4)27.04%
Revenue beat(8)4
Avg Revenue beat(8)49.08%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.65%
PT rev (3m)19.12%
EPS NQ rev (1m)0.03%
EPS NQ rev (3m)4.13%
EPS NY rev (1m)0%
EPS NY rev (3m)1457.5%
Revenue NQ rev (1m)-14.14%
Revenue NQ rev (3m)-24.82%
Revenue NY rev (1m)20.06%
Revenue NY rev (3m)70.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 55.18
P/S 144.33
P/FCF 118.43
P/OCF 115.16
P/B 10.8
P/tB 10.8
EV/EBITDA N/A
EPS(TTM)-2.05
EYN/A
EPS(NY)1.89
Fwd EY1.81%
FCF(TTM)0.88
FCFY0.84%
OCF(TTM)0.9
OCFY0.87%
SpS0.72
BVpS9.63
TBVpS9.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -19.48%
ROE -21.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 121.87%
ROA(3y)-1.53%
ROA(5y)-18.42%
ROE(3y)-1.29%
ROE(5y)-20.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 124.22%
Cap/Sales 3.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.71
Quick Ratio 12.71
Altman-Z 72.34
F-Score4
WACC9.17%
ROIC/WACCN/A
Cap/Depr(3y)63.14%
Cap/Depr(5y)80.58%
Cap/Sales(3y)1.59%
Cap/Sales(5y)2.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-148.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-134.85%
EPS Next Y192.01%
EPS Next 2Y29.39%
EPS Next 3Y34.01%
EPS Next 5Y30.02%
Revenue 1Y (TTM)-89.41%
Revenue growth 3Y20.07%
Revenue growth 5Y9.96%
Sales Q2Q%-95.64%
Revenue Next Year764.28%
Revenue Next 2Y74.93%
Revenue Next 3Y74.94%
Revenue Next 5Y63.29%
EBIT growth 1Y-162.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year259.07%
EBIT Next 3Y48.73%
EBIT Next 5YN/A
FCF growth 1Y-69.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.68%
OCF growth 3YN/A
OCF growth 5YN/A

PROTAGONIST THERAPEUTICS INC / PTGX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for PROTAGONIST THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 5 / 10 to PTGX.


What is the valuation status for PTGX stock?

ChartMill assigns a valuation rating of 4 / 10 to PROTAGONIST THERAPEUTICS INC (PTGX). This can be considered as Fairly Valued.


Can you provide the profitability details for PROTAGONIST THERAPEUTICS INC?

PROTAGONIST THERAPEUTICS INC (PTGX) has a profitability rating of 2 / 10.